Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2, Open-label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Letrozole Plus Pd 0332991 (Oral Cdk 4/6 Inhibitor) And Letrozole Single Agent For The First-line Treatment Of Er Positive, Her2 Negative Advanced Breast Cancer In Postmenopausal Women

Trial Profile

Phase 1/2, Open-label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Letrozole Plus Pd 0332991 (Oral Cdk 4/6 Inhibitor) And Letrozole Single Agent For The First-line Treatment Of Er Positive, Her2 Negative Advanced Breast Cancer In Postmenopausal Women

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs Letrozole (Primary) ; Palbociclib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PALOMA-1
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 24 Jul 2018 Results (n=1352) of pooled analysis of PALOMA studies (NCT00721409, NCT01740427 and NCT01942135) published in the European Journal of Cancer
    • 18 Jul 2018 Pooled data from PALOMA-1, PALOMA-2 and PALOMA-3 studies were published in the Journal of the National Cancer Institute
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top